Supernus Pharmaceuticals Balances Record Sales With Rising Costs
Supernus Pharmaceuticals ((SUPN)) has held its Q4 earnings call. Read on for the main highlights of the call.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Supernus Pharmaceuticals’ latest earnings call carried a cautiously upbeat tone, as management spotlighted record 2025 revenue and strong momentum across its key products while acknowledging the sting of higher costs and a swing to a GAAP loss. Investors heard a story of accelerating commercial traction and a deeper pipeline, tempered by integration expenses, supply risks and pressure on profitability in the near term.
Record Sales Mark a Transformational 2025
Supernus reported record full‑year 2025 revenue of $719 million, fueled by its growing neurology portfolio and the Sage acquisition. Management framed the year as a turning point in scale, with new assets broadening the franchise even as integration costs temporarily weighed on earnings.
Growth Products Now Dominate the Revenue Mix
The company’s four growth drivers — Qelbree, GOCOVRI, ZURZUVAE and ONAPGO — showed a company‑stated 40% revenue increase and supplied roughly 76% of total revenue in the fourth quarter. This mix shift underscores a business increasingly anchored in higher‑growth brands rather than legacy products.
ONAPGO Shows Early Momentum Amid Supply Constraints
ONAPGO generated $8.9 million in Q4 net sales, up from $6.8 million in Q3, bringing first‑year revenue to $17.3 million with prescriptions up nearly 30% quarter over quarter. The company expects $45 million to $70 million of ONAPGO sales in 2026 and says its current supplier can cover demand, though earlier disruptions have left a sizable backlog.
ZURZUVAE Surges After Sage Acquisition
ZURZUVAE posted $32.8 million of collaboration revenue in Q4 and $53 million over the five months since the Sage transaction closed. Biogen‑reported U.S. sales soared about 187% year over year and 19% sequentially, with prescribers doubling and total prescriptions rising more than 150%, highlighting rapid adoption of this recently acquired asset.
Qelbree Maintains Double‑Digit Growth Trajectory
Qelbree surpassed $300 million in 2025 net sales, up 26% from 2024, supported by 21% growth in total annual prescriptions. Adult demand rose 29% and pediatric prescriptions increased 18%, though Q4 net sales growth was limited to 9% year over year by gross‑to‑net pressure and a one‑time $4 million PBM adjustment.
GOCOVRI Delivers Steady, Durable Expansion
GOCOVRI contributed $146 million in 2025 net sales, a 12% year‑over‑year increase, with about 67,000 prescriptions written, up 14%. Fourth‑quarter net sales reached $38.6 million and prescriptions climbed 16% versus the prior year, reinforcing the brand’s role as a stable growth pillar in the portfolio.
Non‑GAAP Earnings Remain Solid but Off the Peak
Adjusted non‑GAAP operating earnings were $48.5 million in Q4, essentially flat versus last year, and $158.7 million for full‑year 2025. Management guided 2026 non‑GAAP operating earnings to a range of $140 million to $170 million, indicating continued investment but a commitment to maintaining healthy underlying profitability.
Pipeline Advances Broaden Future Optionality
Supernus highlighted R&D progress, including initiation of a Phase IIb trial for SPN‑820 in roughly 200 adults with major depressive disorder and ongoing Phase IIb work for SPN‑817 in about 258 focal seizure patients. SPN‑443 is expected to enter Phase I in the second half of 2026, while select early‑stage Sage assets are being evaluated for retention or partnering.
Balance Sheet Supports Further Deals and Development
The company closed 2025 with approximately $309 million in cash, cash equivalents and marketable securities, down from $454 million a year earlier, and carries no debt. Management emphasized that despite the Sage outlay, the balance sheet remains flexible enough to pursue additional business development and M&A when opportunities arise.
GAAP Profits Hit by Acquisition‑Driven Cost Surge
On a GAAP basis, Supernus swung to a 2025 operating loss of $62.3 million from operating income of $81.7 million in 2024, producing a net loss of $38.6 million versus prior‑year net income of $73.9 million. The company cited significantly higher R&D and SG&A, including roughly $73 million of acquisition costs and about $50 million of Sage‑related operating expenses.
Operating Expense Inflation Pressures Adjusted Earnings
Combined R&D and SG&A climbed to $591.8 million in 2025, up about 37.5% from 2024, reflecting the larger commercial footprint and integration spending. As a result, non‑GAAP adjusted operating earnings fell to $158.7 million from $183.7 million, even as the revenue base expanded.
Qelbree Economics and ONAPGO Supply Remain Watch Points
Qelbree’s full‑year gross‑to‑net finished near 49%, and management now expects it to run between 50% and 55% in 2026, highlighting ongoing payer and rebate pressure. For ONAPGO, earlier supply constraints created a backlog of enrollment forms and patients, and while a second supplier is being lined up for 2027, regulatory and timing risks could affect future capacity.
Short‑Term GAAP Loss Extends Into the Fourth Quarter
In Q4 2025, Supernus posted a GAAP operating loss of $4 million and a net loss of $4.1 million, compared with net earnings of $15.3 million a year earlier. The quarter’s results were weighed down by Sage‑related operating costs and higher intangible amortization, reinforcing the near‑term earnings drag from the acquisition.
Guidance Points to Continued Growth with Investment
For 2026, management guided to total revenue of $840 million to $870 million, implying another year of solid top‑line expansion, with ONAPGO expected to contribute $45 million to $70 million in sales. The company plans combined R&D and SG&A of $620 million to $650 million, GAAP operating income ranging from breakeven to a $30 million loss, and non‑GAAP operating earnings between $140 million and $170 million, while reiterating Qelbree’s 50% to 55% gross‑to‑net range.
Supernus’ earnings call painted a picture of a company trading near‑term GAAP profitability for scale, portfolio depth and pipeline optionality. For investors, the key questions will be whether management can convert record revenue and strong product momentum into sustained non‑GAAP earnings growth while navigating cost inflation, payer dynamics and ONAPGO supply execution in the coming years.
